Cell-based Approaches to Treating Parkinson's Disease: From Preclinical Studies to Clinical Trial


Friday, October 16, 2020, 12:30pm to 2:00pm


Virtual, via Zoom - register to receive the link via email

Hosted by HMS Center for Bioethics | Ethics in Research & Biotechnology

Click here to register.

Guest speaker:
Lorenz Studer, MD

DIrector, Center for Stem Cell Biology
Memorial Sloan Kettering Cancer Center

Insoo Hyun, PhD

DIrector of Research Ethics, Center for Bioethics
Harvard Medical School

Professor of Bioethics
Case Western Reserve University School of Medicine


Lorenz Studer's lab has worked for over a decade on developing a cell therapy for Parkinson's disease (PD). Recently Dr. Studer has demonstrated that lab-grown dopamine nerve cells derived from human stem cells can efficiently engraft and function in animal models of PD. Based on these results, the Studer lab is pursuing the development of a clinical-grade dopamine neuron cell product and is in the process of generating the data necessary for an investigational new drug application from the FDA, which is required for the first human clinical use of human ESC-derived dopamine neurons.

This consortium will examine the major milestones of Dr. Studer's work as he advances his promising cell-based approach to treating Parkinson's disease, from preclinical studies to clinical trials. Together, Dr. Insoo Hyun and Dr. Studer will discuss the ethical issues that track alongside this exciting scientific journey to the clinic and will invite the audience to participate in interactive discussion.

Register and add upcoing seesions to your calendar now:


November 20, 2020

How Brain Organoids Can Help Advance COVID-19 Research

December 11, 2020

Right to Try Laws and Their Impact on Research and Patient Access